Chinese venture capital investment into US biotech companies in the first half has already surpassed the record set for the whole of last year, underlining Beijing’s focus on medicine as a strategic sector — a development that has flown under the radar of regulators in Washington.
今年上半年manbetx3.0 风险资本对美国生物技术公司的投资已经超出去年全年的创纪录水平，突显北京方面对医药作为一个战略行业的关注——这一动向迄今没有受到华盛顿的监管者关注。
您已阅读7%（361字），剩余93%（4527字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。